Alkermes (ALKS) Q1 2026 Earnings Transcript

Alkermes reported Q1 total revenue of $392.9 million and adjusted EBITDA of $80.3 million, both ahead of expectations, while raising full-year visibility through improved 2026 GAAP loss, COGS, amortization, and tax assumptions tied to the Avadel acquisition. LUMRYZ contributed $72 million of quarterly revenue and the company reaffirmed strong 2026 product guidance, including VIVITROL at $460 million to $480 million and ARISTADA at $365 million to $385 million. Pipeline progress was also notable, with Alixorexton Phase III enrollment underway and new orexin programs entering ADHD and fatigue, supporting a constructive long-term growth narrative.

Analysis

ALKS is transitioning from a single-asset growth story into a two-engine model: cash-generating sleep medicine plus a long-dated orexin call option. The key second-order effect is commercial leverage: LUMRYZ gives the company a live payer/specialist footprint before Alixorexton launches, which should lower future CAC and improve conversion if the narcolepsy franchise expands as intended. That makes the Avadel integration more strategically valuable than the near-term revenue contribution alone, because it shortens the commercialization learning curve for a future category leader.

The market is likely underestimating how much of the 2026 narrative is already de-risked by execution rather than discovery. The next 2-3 catalysts are mostly binary but staggered: REVITALYZ data in IH, Brilliance enrollment progress, and first ADHD proof-of-concept results. If ADHD translational data show even partial dose-response on attention/impulsivity, the valuation framework should shift from “sleep drug company” to “platform with adjacent indications,” which can re-rate the multiple before any registrational data arrive.

The main risks are not clinical strength but financing of ambition and future erosion math. R&D intensity is stepping up while the tax shield is weaker, and management is relying on rapid debt paydown to preserve flexibility; any slip in LUMRYZ uptake or pipeline timing would quickly compress the equity story. For TEVA, the overhang looks more like scenario uncertainty than a clean near-term dislocation: VIVITROL is exposed in 2027, but the company is signaling a durability profile that could blunt a generic launch more than investors expect. That makes the bear case more about multiple compression from perceived execution risk than about an imminent fundamentals cliff.

Key Decisions for Investors

• Long ALKS on a 3-6 month horizon into the REVITALYZ and ADHD data window; best risk/reward is via call spreads rather than stock if you want upside convexity with defined downside.
• Add on pullbacks rather than chasing strength: use any post-earnings volatility to build a position if the market discounts the pipeline because of higher R&D spend; the spend is the bridge to multiple expansion, not a sign of distress.
• Pair trade: long ALKS / short TEVA into 2027 generic-VIVITROL headlines; ALKS has cleaner self-help and multiple catalysts, while TEVA carries launch uncertainty without comparable offsetting growth drivers.
• For event-driven accounts, buy near-dated ALKS calls ahead of the REVITALYZ readout and first ADHD data, but hedge with stock or puts after the data if the market starts pricing in aggressive peak-sales assumptions too early.
• Avoid over-sizing a long until LUMRYZ + Alixorexton commercialization evidence is visible; the bear case is a slower-than-expected adoption curve that would limit near-term deleveraging and cap multiple expansion.